PMID: 6406930Mar 1, 1983Paper

Behavioral and neurochemical effects of neurotensin microinjection into the ventral tegmental area of the rat

Neuroscience
P W KalivasA J Prange

Abstract

The ventral tegmental area of the rat brain has been shown to possess high densities of neurotensin- and dopamine-containing neuronal perikarya. We recently demonstrated that microinjection of neurotensin into the ventral tegmental area produces behavioral hyperactivity similar to amphetamine-induced increase in exploratory behaviors, but lacking stereotypies. In this study, we report that the threshold dose for neurotensin-induced hyperactivity is 0.10-0.25 micrograms neurotensin/side. Either intracerebroventricular injection of haloperidol (5.0 micrograms/lateral ventricle) or destruction of the mesolimbic dopamine system by 6-hydroxydopamine abolishes the behavioral hyperactivity produced by intraventral tegmental injection of neurotensin (2.5 micrograms/side). Using high pressure liquid chromatography with electrochemical detection, we show that neurotensin injection into the ventral tegmental area increases the concentration of dopamine metabolites, 3,4-dihydroxyphenylacetic acid and homovanillic acid in the nucleus accumbens and olfactory tubercles, but not in the striatum. This effect is especially profound in the nucleus accumbens where the threshold dose is less than 0.025 micrograms/side. The ratio of 3,4-dihydroxyphe...Continue Reading

References

Feb 15, 1978·The Journal of Comparative Neurology·R Y Moore
Jan 1, 1979·Brain Research Bulletin·K KataokaL A Frohman
Jan 15, 1978·Experientia·P WolfH L Haas
Jun 30, 1978·Brain Research·A C CuelloT Jessell
Sep 1, 1979·The Journal of Comparative Neurology·O T Phillipson
Jan 1, 1978·Annual Review of Neuroscience·R Y Moore, F E Bloom
Jul 1, 1980·Journal of the Autonomic Nervous System·K B HelleR Knudsen
Sep 20, 1982·The Journal of Comparative Neurology·L JennesP W Kalivas
Jan 1, 1982·Annals of the New York Academy of Sciences·P W KalivasA J Prange
Jan 1, 1981·Schizophrenia Bulletin·D H LangerJ P Docherty

❮ Previous
Next ❯

Citations

Dec 1, 1984·Italian Journal of Neurological Sciences·A Albanese, M C Altavista
Jan 1, 1991·Psychopharmacology·L M Colle, R A Wise
Jul 2, 2011·Psychopharmacology·F Scott HallGeorge R Uhl
Nov 27, 1984·European Journal of Pharmacology·S M Simasko, G A Weiland
Jan 26, 1993·European Journal of Pharmacology·J M FerrerJ A Saez
Mar 21, 1994·European Journal of Pharmacology·D Nouel, J Costentin
Apr 1, 1995·Neuropharmacology·A J Stoessl
May 1, 1986·Pharmacology, Biochemistry, and Behavior·M F HawkinsR T Tulley
May 1, 1993·Pharmacology, Biochemistry, and Behavior·A D Campbell, V G Erwin
Aug 1, 1995·Pharmacology, Biochemistry, and Behavior·V G ErwinD E Womer
Jan 1, 1985·Neuroscience and Biobehavioral Reviews·P W Kalivas
Jan 1, 1993·Brain Research. Brain Research Reviews·P W Kalivas
Jan 1, 1994·Brain Research. Brain Research Reviews·J A Angulo, B S McEwen
Apr 1, 1991·Journal of Neuroscience Methods·R Rivest, C A Marsden
Aug 19, 1991·Brain Research. Developmental Brain Research·C DanaW Rostene
Oct 29, 1991·Regulatory Peptides·J Kasckow, C B Nemeroff
Jan 1, 1988·Peptides·J A StiversJ N Crawley
Jan 1, 1988·Progress in Neuro-psychopharmacology & Biological Psychiatry·G N Ervin, C B Nemeroff

❮ Previous
Next ❯

Related Concepts

Related Feeds

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here